<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01276249</url>
  </required_header>
  <id_info>
    <org_study_id>CD03335-01</org_study_id>
    <nct_id>NCT01276249</nct_id>
  </id_info>
  <brief_title>The STAPLE International Post-Market Registry</brief_title>
  <official_title>The STAPLE-International Post-Market Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Cardiovascular</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Cardiovascular</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Aptus Endosystems STAPLE International Post-Market Registry is intended to expand the&#xD;
      clinical knowledge base by including 'real world' subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Aptus Endosystems STAPLE International Post-Market Registry is intended to expand the&#xD;
      clinical knowledge base by including 'real world' subjects.&#xD;
&#xD;
      All subjects diagnosed with a qualifying AAA suitable for elective endovascular repair, who&#xD;
      meet the inclusion/exclusion criteria for the registry, are eligible for enrollment and&#xD;
      should be offered informed consent to participate.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Medtronic terminated the study since Foretevo product was no longer marketed&#xD;
  </why_stopped>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">June 19, 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Technical Success</measure>
    <time_frame>Within 24 hours of the Index procedure</time_frame>
    <description>The first primary endpoint is primary technical success. It consists of the following items:&#xD;
Successful arterial access&#xD;
Successful deployment of the Fortevo Endograft with secure proximal and distal fixation&#xD;
Absence of type I or III endoleaks&#xD;
Patent Fortevo Endograft without significant twist, kinking, or obstruction</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Major Adverse Events (MAE)</measure>
    <time_frame>Within 1-Month of Implantation</time_frame>
    <description>The second primary endpoint is associated with the safety profile of the device, and is defined as the percent of patients experiencing one or more of major adverse events (MAE) within one month of implantation. MAE are defined as any one of the following events:&#xD;
Death&#xD;
Myocardial Infarction&#xD;
Stroke (excludes TIA)&#xD;
Renal failure (excludes renal insufficiency)&#xD;
Respiratory Failure (excludes COPD or pulmonary complications)&#xD;
Paralysis (excludes paraparesis)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Success and Safety of the Fortevo Endograft and Heli-FX EndoAnchor System components</measure>
    <time_frame>1-Month, 6-Months and 12-Months</time_frame>
    <description>Clinical Success is defined as Successful Deployment of the Fortevo Endograft at the intended location and the absence of:&#xD;
Death as a result of aneurysm-related treatment&#xD;
Type I or III endoleak&#xD;
Fortevo Endograft infection&#xD;
Fortevo Endograft thrombosis&#xD;
Fortevo Endograft dilatation by 20% or more in diameter&#xD;
Fortevo Endograft migration by 10mm or more at the proximal neck at 6-M and 12-M&#xD;
Loss of Fortevo Endograft or Heli-FX EndoAnchor System integrity&#xD;
Aneurysm expansion by 5mm (or more) in maximal diameter at 6-M and 12-M&#xD;
Aneurysm rupture&#xD;
Conversion to open repair</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">108</enrollment>
  <condition>Aortic Aneurysm, Abdominal</condition>
  <condition>Aorto Iliac Aneurysm</condition>
  <arm_group>
    <arm_group_label>Fortevo Endograft</arm_group_label>
    <description>All subjects diagnosed with a qualifying AAA suitable for elective endovascular repair, who meet the inclusion/exclusion criteria for the registry, are eligible for enrollment if treated with the Fortevo Endograft.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Fortevo Endograft</intervention_name>
    <description>The Fortevo Endograft, Main Body and Iliac Lumen Delivery System are indicated for the endovascular treatments of patients with infrarenal abdominal aortic aneurysms or aortic-iliac aneurysms having suitable morphology for endovascular repair.</description>
    <arm_group_label>Fortevo Endograft</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects diagnosed with a qualifying AAA suitable for elective endovascular repair.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient ≥ 18 years old&#xD;
&#xD;
          2. Patient has given written informed consent&#xD;
&#xD;
          3. Patient has a life expectancy &gt; 1 year&#xD;
&#xD;
          4. Patient is willing to comply with follow-up evaluations&#xD;
&#xD;
          5. Patient's AAA meets at least one of the following criteria:&#xD;
&#xD;
               -  ≥ 4.5cm in diameter&#xD;
&#xD;
               -  Increased in size by 0.5cm in last 6 months&#xD;
&#xD;
               -  Maximum diameter exceeds 1.5 times the transverse dimension of an adjacent normal&#xD;
                  aortic segment&#xD;
&#xD;
               -  Saccular aneurysm larger than 3cm in maximal diameter&#xD;
&#xD;
          6. Patient has a proximal aortic neck diameter measured inner wall to inner wall between&#xD;
             19mm and 29mm&#xD;
&#xD;
          7. Patient has a proximal aortic neck length of at least 12mm&#xD;
&#xD;
          8. Patient has a patent iliac or femoral artery that allows endovascular access to the&#xD;
             aneurysmal site with 16Fr (5.3mm) or 18Fr (6.0mm) delivery system.&#xD;
&#xD;
          9. Patient has bilateral iliac artery distal fixation site ≥ 10mm in length with an&#xD;
             internal diameter between 9mm and 20mm&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient is participating in a concurrent clinical study which may confound&#xD;
             STAPLE-International Registry results&#xD;
&#xD;
          2. Patient has a symptomatic AAA&#xD;
&#xD;
          3. Patient's AAA has a proximal aortic neck angle that is &gt; 60 degrees between the&#xD;
             infrarenal neck and the long axis of the aneurysm&#xD;
&#xD;
          4. Patient has irregularly-shaped plaque that would inhibit sealing stent apposition&#xD;
&#xD;
          5. Patient has aortic mural pathology that is ≥ 2mm in thickness over ≥ 50% of the&#xD;
             circumference of the proximal fixation site&#xD;
&#xD;
          6. Patient has an active, or known history of, bleeding diathesis or hypercoagulable&#xD;
             condition&#xD;
&#xD;
          7. Patient has a contraindication to any materials to which he or she will be exposed&#xD;
             during the EVAR procedure (i.e., Fortevo Endograft or Heli-FX EndoAnchor System&#xD;
             materials, contrast agents)&#xD;
&#xD;
          8. Patient has a genetic connective tissue disorder (e.g., Marfan's or Ehlers-Danloe&#xD;
             Syndromes)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Paul de Vries, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St Antonius Hospital - Nieuwegein, Netherlands</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sherbrooke University Hospital Centre</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>German Heart Center</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Center Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Bonifatious Hospital</name>
      <address>
        <city>Lingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hellenic Airforce Hospital</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Siena</name>
      <address>
        <city>Siena</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Antonious Hospital</name>
      <address>
        <city>Nieuwegein</city>
        <zip>3430</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thorax Institute Hospital Clinic</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Navarra</name>
      <address>
        <city>Pamplona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
  </location_countries>
  <removed_countries>
    <country>Austria</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
  </removed_countries>
  <reference>
    <citation>Deaton DH. Future technologies to address the failed endoprosthesis. Semin Vasc Surg. 2009 Jun;22(2):111-8. doi: 10.1053/j.semvascsurg.2009.04.010. Review.</citation>
    <PMID>19573751</PMID>
  </reference>
  <results_reference>
    <citation>Deaton DH, Mehta M, Kasirajan K, Chaikof E, Farber M, Glickman MH, Neville RF, Fairman RM. The phase I multicenter trial (STAPLE-1) of the Aptus endovascular repair system: results at 6 months and 1 year. J Vasc Surg. 2009 Apr;49(4):851-7; discussion 857-8. doi: 10.1016/j.jvs.2008.10.064.</citation>
    <PMID>19341879</PMID>
  </results_reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>January 11, 2011</study_first_submitted>
  <study_first_submitted_qc>January 11, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2011</study_first_posted>
  <last_update_submitted>October 27, 2021</last_update_submitted>
  <last_update_submitted_qc>October 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Aptus Endosystem</keyword>
  <keyword>EndoStaple</keyword>
  <keyword>Endograft</keyword>
  <keyword>Stent Graft</keyword>
  <keyword>Abdominal Aortic Aneurysm</keyword>
  <keyword>Heli-FX</keyword>
  <keyword>EndoAnchor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aneurysm</mesh_term>
    <mesh_term>Aortic Aneurysm</mesh_term>
    <mesh_term>Aortic Aneurysm, Abdominal</mesh_term>
    <mesh_term>Iliac Aneurysm</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

